journal
https://read.qxmd.com/read/38312516/clinical-significance-of-integrin-%C3%AE-v-and-%C3%AE-superfamily-members-and-focal-adhesion-kinase-activity-in-oral-squamous-cell-carcinoma-a-retrospective-observational-study
#21
JOURNAL ARTICLE
Shigeru Sakurai, Yasutaka Ishida, Tomoaki Shintani, Sachiko Yamasaki, Kensaku Matsui, Tomoaki Hamana, Tadayoshi Nobumoto, Souichi Yanamoto, Yasutaka Hayashido
Objectives: Integrins are heterodimeric transmembrane plasma membrane proteins composed of α- and β-chains. They bind to extracellular matrix (ECM) and cytoskeletal proteins as ECM protein receptors. Upon ECM protein binding, integrins activate focal adhesion kinase (FAK) and transduce various signals. Despite their importance, integrin and FAK expression in oral squamous cell carcinoma (OSCC) tissue and the prognosis of patients with OSCC remains elusive. Methods: In a retrospective observational study, we immunohistochemically evaluated integrin αV, β1, β3, β5, β6, FAK, and phosphorylated-FAK (pFAK) expressions as prognostic predictors in 96 patients with OSCC...
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38273861/analysis-of-hif-1%C3%AE-expression-and-genetic-polymorphisms-in-human-clear-cell-renal-cell-carcinoma
#22
JOURNAL ARTICLE
Daniela Vargova, Zuzana Kolková, Jan Dargaj, Lukas Bris, Jan Luptak, Zuzana Dankova, Sona Franova, Jan Svihra, Pavol Slávik, Martina Sutovska
Introduction: Clear cell renal cell carcinoma (ccRCC) is mostly diagnosed incidentally and has relatively high recurrence rates. Alterations in VHL/HIF and mTOR pathways are commonly present in ccRCC. The present study attempted to identify potential diagnostic markers at the biochemical and molecular level. Methods: In total, 54 subjects (36 patients with ccRCC and 18 cancer-free controls) were enrolled. ELISA was used to measure the levels of HIF-1α in the tumor and healthy kidney tissue. The association between five selected SNPs (rs779805, rs11549465, rs2057482, rs2295080 and rs701848) located in genes of pathologically relevant pathways (VHL/HIF and mTOR) and the risk of ccRCC in the Slovak cohort was studied using real-time PCR...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38273860/clinical-and-pathological-observation-of-conversion-therapy-for-malignant-peritoneal-mesothelioma-a-case-report-and-literature-review
#23
Minying Deng, Xinyi Zhang, Chen Xu, Rongkui Luo, Lingli Chen, Yuhong Zhou, Yingyong Hou
Background: Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse MM: epithelioid, sarcomatoid, desmoplastic, and biphasic, with biphasic being less common. The onset of this tumor is insidious, and the prognosis is extremely poor in some cases, with a median survival of 6-18 months and no standard treatment options in the past. Aims: We report a case of peritoneal malignant mesothelioma that was successfully treated with transformative therapy...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38239282/supratentorial-meningeal-melanocytoma-mimicking-meningioma-case-report-and-literature-review
#24
Mayle Gomes Ferreira de Araújo, Luiz Euripedes Almondes Santana Lemos, Pedro Lucas Negromonte Guerra, Fernanda Marcia Dos Santos Lima Didjurgeit, Auricelio Batista Cezar, Igor Vilela Faquini, Hildo Rocha Cirne de Azevedo Filho
Introduction: Primary melanocytic tumors originating from CNS melanocytes are rare, with a low incidence of 0.7 cases per 10 million annually. This study focuses on primary leptomeningeal melanocytomas, emphasizing their epidemiology, clinical characteristics, and diagnostic challenges. Despite their infrequency, these tumors warrant attention due to their unique features and potential for local recurrence. Case Report: A 32-year-old female presented with syncope and seizures, leading to the discovery of two left-sided supratentorial lesions initially misidentified as convexity meningiomas...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38239281/krasg12c-mutant-lung-adenocarcinoma-unique-biology-novel-therapies-and-new-challenges
#25
REVIEW
Judit Moldvay, József Tímár
KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant that allele specific irreversible inhibitors have been developed for the smoking associated G12C mutant KRAS (sotorasib and adagrasib)...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38188613/the-prognostic-value-of-stem-cell-markers-in-triple-negative-breast-cancer
#26
JOURNAL ARTICLE
Szintia Almási, Ágnes Nagy, Tibor Krenács, Tamás Lantos, Tamás Zombori, Gábor Cserni
Among the many consecutive theories of cancer, the stem cell theory is currently the most accepted one. Cancer stem cells are located in small niches with specific environment, renew themselves and are believed to be responsible for many recurrences. They can be highlighted with stem cell markers, but often these markers also label tumor cells, and this may represent a phenotypical change associated with prognosis. In this study, we attempted to match tumor outcomes with the expression of the following stem cell markers: ALDH1, AnnexinA1, CD44, CD117, CD166, Nanog and oct-4...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38188612/urachus-adenocarcinoma-mistaken-for-umbilical-incision-implant-cancer-after-laparoscopic-cholecystectomy-a-case-report
#27
Yanxing Mai, Lei Feng, Zhenxi Liu, Yu Nie, Zesheng Jiang, Jiasheng Qin
Umbilical incision implant cancer after LC is rare. Elective cholecystectomy was planned for a 49 years-old female patient with symptomatic gallstones. The patient underwent transumbilical single-port LC after admission to our hospital. Gallbladder specimens were obtained directly through the umbilical puncture hole, and histopathology suggested chronic cholecystitis. Three months after surgery, the patient experienced painful induration in the umbilicus. We initially considered incision scar hyperplasia complicated with pain, and used drugs to treat it conservatively without taking special treatment measures...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38188611/pancreatic-sabr-using-peritumoral-fiducials-triggered-imaging-and-breath-hold
#28
JOURNAL ARTICLE
Katalin Kisivan, Andrea Farkas, Peter Kovacs, Csaba Glavak, Gabor Lukacs, Karoly Mahr, Zsolt Szabo, Melinda Petone Csima, Akos Gulyban, Zoltan Toth, Zsolt Kaposztas, Ferenc Lakosi
Background: We aim to present our linear accelerator-based workflow for pancreatic stereotactic ablative radiotherapy (SABR) in order to address the following issues: intrafractional organ motion management, Cone Beam CT (CBCT) image quality, residual errors with dosimetric consequences, treatment time, and clinical results. Methods: Between 2016 and 2021, 14 patients with locally advanced pancreatic cancer were treated with induction chemotherapy and SABR using volumetric modulated arc therapy (VMAT). Internal target volume (ITV) concept (5), phase-gated (4), or breath hold (5) techniques were used...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38188610/spectrum-of-bcr-abl-mutations-in-azerbaijanian-imatinib-resistant-patients-with-chronic-myeloid-leukemia
#29
JOURNAL ARTICLE
Aypara Hasanova, Chingiz Asadov, Nigar Karimova, Aytan Shirinova, Gunay Aliyeva, Zohra Alimirzoyeva
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Here, we present the first report of the spectrum of mutations in the BCR-ABL1 KD of CML patients from Azerbaijan. Materials and methods: Samples for mutation screening were obtained from patients experiencing resistance to first line TKIs or from patients in acceleration phase (AP) or blast crisis (BC) at the time of diagnosis. The cDNA region corresponding to BCR-ABL1 KD was sequenced by pyrosequencing method...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38170116/retraction-frequencies-of-porphyromonas-gingivalis-detection-in-oral-digestive-tract-tumors
#30
(no author information available yet)
[This retracts the article DOI: 10.3389/pore.2021.628942.].
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38155817/retraction-associations-of-porphyromonas-gingivalis-infection-and-low-beclin1-expression-with-clinicopathological-parameters-and-survival-of-esophageal-squamous-cell-carcinoma-patients
#31
(no author information available yet)
[This retracts the article DOI: 10.3389/pore.2021.1609976.].
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38146588/comparative-analysis-of-ezh2-p16-and-p53-expression-in-uterine-carcinosarcomas
#32
JOURNAL ARTICLE
Evelin Makk, Noémi Bohonyi, Angéla Oszter, Klára Éles, Tamás Tornóczky, Arnold Tóth, Endre Kálmán, Krisztina Kovács
Introduction: The role of p16 and p53 immunohistochemistry in the diagnosis of rare and aggressive uterine carcinosarcoma (UCS) has been well established. However, enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a member of the polycomb group family is a relatively new biomarker, with limited published data on its significance in this tumor type. The goal of this study was to examine EZH2 expression in UCS and its components, in correlation with morphological features, and p16 and p53 staining patterns...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38099242/conjoint-analysis-of-clinical-imaging-and-pathological-features-of-schistosomiasis-and-colorectal-cancer
#33
JOURNAL ARTICLE
Fang Zhang, XiaoShuang Wang, YuanTing Zhu, Peng Xia
This study aims to examine and compare clinical, radiological, and pathological data between colorectal cancer (CRC) patients with and without schistosomiasis and uncover distinctive CRC characteristics when accompanied by schistosomiasis. This retrospective study is based on data collected from 341 patients diagnosed with CRC post-surgery and pathology. Of these patients, 101 (Group A) were diagnosed with colorectal cancer co-occurring with schistosomiasis (CRC-S), while 240 patients (Group B) were diagnosed with colorectal cancer without concurrent schistosomiasis (CRC-NS)...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38099241/quantitative-analysis-of-endobronchial-elastography-combined-with-serum-tumour-markers-of-lung-cancer-in-the-diagnosis-of-benign-and-malignant-mediastinal-and-hilar-lymph-nodes
#34
JOURNAL ARTICLE
Zhen Wang, Peng Li, Jiayu Bai, Yujia Liu, Guangyu Jiao
Purpose: In malignant tumours, elastography and serum tumour markers have shown high diagnostic efficacy. Therefore, we aimed to quantitatively analyse the results of endobronchial elastography combined with serum tumour markers of lung cancer to accurately distinguish benign and malignant mediastinal and hilar lymph nodes. Methods: Data of patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal lymph node enlargement in our hospital between January 2018 and August 2022 were retrospectively collected...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38089646/case-report-squamous-cell-carcinoma-of-the-prostate-a-clinicopathological-and-genomic-sequencing-based-investigation
#35
Caixin Zhang, Yong Jia, Qingnuan Kong
Squamous differentiation of prostate cancer, which accounts for less than 1% of all cases, is typically associated with androgen deprivation treatment (ADT) or radiotherapy. This entity is aggressive and exhibits poor prognosis due to limited response to traditional treatment. However, the underlying molecular mechanisms and etiology are not fully understood. Previous findings suggest that squamous cell differentiation may potentially arise from prostate adenocarcinoma (AC), but further validation is required to confirm this hypothesis...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38025907/long-term-follow-up-of-refractory-relapsed-hairy-cell-leukaemia-patients-treated-with-low-dose-vemurafenib-between-2013-and-2022-at-the-department-of-internal-medicine-and-oncology-semmelweis-university
#36
JOURNAL ARTICLE
Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter
Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. BRAF V600E mutation is detected in nearly all classical HCL cases which offers the possibility of targeted therapy. Objective: The aim of our study was to assess the efficacy of low-dose vemurafenib as well as to assess the long term outcome of HCL patients treated with this drug at the Department of Internal Medicine and Oncology at Semmelweis University. Methods: We report on 10 patients with classical HCL treated with low-dose vemurafenib at our Department between 2013 and 2022...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38025906/erratum-expression-of-concern-case-report-a-rare-case-of-tumor-to-tumor-metastasis-metastatic-lobular-breast-carcinoma-to-clear-cell-renal-cell-carcinoma
#37
(no author information available yet)
[This corrects the article DOI: 10.3389/pore.2023.1611204.].
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/38025905/effective-venetoclax-based-treatment-in-relapsed-refractory-multiple-myeloma-patients-with-translocation-t-6-14
#38
JOURNAL ARTICLE
Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala
Introduction : The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains less investigated. Methods: In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/37920248/recent-advances-and-future-directions-in-etiopathogenesis-and-mechanisms-of-reactive-oxygen-species-in-cancer-treatment
#39
REVIEW
Priyanka Verma, Bhavika Rishi, Noreen Grace George, Neetu Kushwaha, Himanshu Dhandha, Manpreet Kaur, Ankur Jain, Aditi Jain, Sumita Chaudhry, Amitabh Singh, Fouzia Siraj, Aroonima Misra
A class of exceptionally bioactive molecules known as reactive oxygen species (ROS) have been widely studied in the context of cancer. They play a significant role in the etiopathogenesis for cancer. Implication of ROS in cancer biology is an evolving area, considering the recent advances; insights into their generation, role of genomic and epigenetic regulators for ROS, earlier thought to be a chemical process, with interrelations with cell death pathways- Apoptosis, ferroptosis, necroptosis and autophagy has been explored for newer targets that shift the balance of ROS towards cancer cell death...
2023: Pathology Oncology Research: POR
https://read.qxmd.com/read/37886029/a-new-perspective-on-the-proper-timing-of-radiotherapy-during-cdk4-6-inhibitor-therapy-in-patients-with-bone-only-metastatic-breast-cancer
#40
REVIEW
Ilona Tornyi, Peter Árkosy, Ildikó Horváth, Andrea Furka
The vast majority of hormone positive and HER2 negative advanced breast cancers can be controlled well by endocrine therapy combined with the groundbreaking use of CDK4/6 inhibitors in the metastatic first-line setting. Approximately 50%-60% of these patients have "bone-only" metastatic disease. In oligometastatic cases or if a certain number of uncontrolled lesions develop during the aforementioned therapy, ablative radiotherapy can be delivered or, in symptomatic cases, urgent irradiation is needed with palliative intent...
2023: Pathology Oncology Research: POR
journal
journal
32724
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.